gemcitabine,cisplatin,carboplatin,enfortumab,pembrolizumab
astellas,seagen,merck
[' cis ', ' uc,(-ucsd),(-ucsf),', 'pembro', 'ev302', 'ev103']
updated ev103 for ev/pembro in 1st line cis ineligible uc looks good (rr 73%, mpfs 12 mnths, mos 26 mnths), 3 yr os ~40 % is exceptional (n= only 45). no new long-term safety issues: note peripheral neuropathy (55%). fda approved with r3 ev302 awaited. #asco2023 
Interested in Urology Cancers, biomarkers and drug development.